Up­dat­ed: FDA clears first CD20xCD3 bis­pe­cif­ic, giv­ing Genen­tech leg up in a crowd­ed lym­phoma R&D field

The first CD20xCD3 bis­pe­cif­ic an­ti­body will soon be­come avail­able in the US fol­low­ing an FDA ap­proval dis­closed Thurs­day night, Dec. 22.

Roche and Genen­tech’s mo­sune­tuzum­ab …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.